GH Research plc (GHRS): Price to Sales

High patent barriers and strict FDA controls limit access to the psychedelics market. The revenue multiple dynamics illustrate the market response, where the value of corresponds to the current metric. GH Research PLC (GHRS) revenues will be based on depression therapy, as the company currently has no sales. The asset's capitalization depends on clinical phases, remaining independent of macroeconomics.

For GH Research PLC (GHRS), which is currently in the stage of costly clinical trials, current revenue is minimal, making the price-to-sales ratio an indicator of market expectations for a future patent monopoly. This chart compares market capitalization with actual sales, allowing investors to distinguish the fundamental value of potential super-margins from speculative noise and determine a safe entry point into the asset.